Published in J Biol Chem on December 03, 2007
Magic angle spinning NMR analysis of beta2-microglobulin amyloid fibrils in two distinct morphologies. J Am Chem Soc (2010) 1.30
A common beta-sheet architecture underlies in vitro and in vivo beta2-microglobulin amyloid fibrils. J Biol Chem (2008) 1.14
Understanding the complex mechanisms of β2-microglobulin amyloid assembly. FEBS J (2011) 1.09
Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin. J Mol Biol (2011) 1.02
Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry (2011) 0.98
Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem (2010) 0.96
Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry (2011) 0.90
Systemic amyloidosis: lessons from β2-microglobulin. J Biol Chem (2015) 0.89
Characterization of the response of primary cells relevant to dialysis-related amyloidosis to β2-microglobulin monomer and fibrils. PLoS One (2011) 0.86
Assembly of the fungal SC3 hydrophobin into functional amyloid fibrils depends on its concentration and is promoted by cell wall polysaccharides. J Biol Chem (2009) 0.85
Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers. J Biol Chem (2013) 0.83
Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin. J Biol Chem (2013) 0.83
Synthetic lipid vesicles recruit native-like aggregates and affect the aggregation process of the prion Ure2p: insights on vesicle permeabilization and charge selectivity. Biophys J (2009) 0.83
The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence. J Mol Biol (2013) 0.82
Inhibition of beta2-microglobulin amyloid fibril formation by alpha2-macroglobulin. J Biol Chem (2011) 0.82
Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys Chem (2011) 0.81
Heparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitro. PLoS One (2011) 0.80
C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype. PLoS One (2012) 0.80
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Sci Rep (2016) 0.78
Wild type beta-2 microglobulin and DE loop mutants display a common fibrillar architecture. PLoS One (2015) 0.78
Misfolding of amyloidogenic proteins and their interactions with membranes. Biomolecules (2013) 0.77
Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J (2017) 0.77
Comparison of the aggregation of homologous β2-microglobulin variants reveals protein solubility as a key determinant of amyloid formation. J Mol Biol (2016) 0.76
Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity. PLoS Pathog (2010) 0.76
Mechanistic Contributions of Biological Cofactors in Islet Amyloid Polypeptide Amyloidogenesis. J Diabetes Res (2015) 0.76
Hydrophobin Vmh2-glucose complexes self-assemble in nanometric biofilms. J R Soc Interface (2012) 0.76
Role of parnaparin in atherosclerosis. Int J Exp Pathol (2017) 0.75
Heparin-induced amyloid fibrillation of β2 -microglobulin explained by solubility and a supersaturation-dependent conformational phase diagram. Protein Sci (2017) 0.75
Influence of heparin molecular size on the induction of C- terminal unfolding in β2-microglobulin. Mol Biol Res Commun (2016) 0.75
Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting. Front Mol Biosci (2016) 0.75
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology (2007) 3.73
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Smoking and colorectal cancer: a meta-analysis. JAMA (2008) 3.19
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. Oncology (Williston Park) (2010) 2.06
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Compliance with therapy in hypertensive patients. Intern Emerg Med (2006) 1.66
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res (2007) 1.58
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood (2011) 1.58
Comparative genome analysis of Trichophyton rubrum and related dermatophytes reveals candidate genes involved in infection. MBio (2012) 1.55
Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol (2010) 1.53
beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem (2005) 1.48
Evolution of emphysema in relation to smoking. Eur Radiol (2009) 1.47
The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci (2002) 1.44
A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet (2005) 1.43
Appropriate use of magnetic resonance imaging and ultrasound to detect early silicone gel breast implant rupture in postmastectomy reconstruction. Plast Reconstr Surg (2014) 1.39
The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist (2008) 1.39
Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant. Proc Natl Acad Sci U S A (2011) 1.38
Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev (2012) 1.37
Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem (2009) 1.34
Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem (2006) 1.33
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
Rapid proton-detected NMR assignment for proteins with fast magic angle spinning. J Am Chem Soc (2014) 1.29
Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis (2006) 1.27
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J Mol Biol (2008) 1.24
Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol (2010) 1.23
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem (2006) 1.22
Vitamin D and skin cancer: a meta-analysis. Eur J Cancer (2008) 1.22
Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid (2006) 1.22
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist (2007) 1.20
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid (2002) 1.18
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. Am J Med Genet A (2010) 1.17
Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol (2006) 1.17
Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer (2009) 1.15
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet (2008) 1.15
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics (2008) 1.14
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 1.14
Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet (2011) 1.12
MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer (2010) 1.10
Antifungal resistance mechanisms in dermatophytes. Mycopathologia (2008) 1.10
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum (2009) 1.10
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.07
Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem (2002) 1.07
Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer (2009) 1.07
The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol (2007) 1.06
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene (2003) 1.06
A major role for side-chain polyglutamine hydrogen bonding in irreversible ataxin-3 aggregation. PLoS One (2011) 1.05
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist (2009) 1.05
RE: Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. J Natl Cancer Inst (2016) 1.05
The workings of the amyloid diseases. Ann Med (2007) 1.04
Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys J (2005) 1.03
Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A (2010) 1.02
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol (2013) 1.02
Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics (2007) 1.01
Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem (2002) 1.01
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Conformational properties of the aggregation precursor state of HypF-N. J Mol Biol (2008) 1.00
Lung cancer in the elderly. J Clin Oncol (2007) 1.00
Combined effect of GSTM1, GSTT1 and GSTP1 polymorphisms on histological subtypes of lung cancer. Biomarkers (2008) 0.99
Molecular diagnosis of analbuminemia: a novel mutation identified in two Amerindian and two Turkish families. Clin Chem (2002) 0.99